Overview
Acromicric dysplasia is a rare skeletal disorder characterized by severe short stature, short hands and feet, and mild facial dysmorphism. The condition is caused by mutations in the FBN1 gene (fibrillin-1), which plays a critical role in the formation of extracellular matrix microfibrils. Acromicric dysplasia belongs to a spectrum of acromelic dysplasias that also includes geleophysic dysplasia and Weill-Marchesani syndrome, all of which can result from specific mutations in FBN1 affecting the TGF-beta signaling pathway. Key clinical features include proportionate short stature that becomes apparent in childhood, with adult height typically ranging from 130 to 150 cm. Affected individuals have characteristically short, stubby hands and feet (brachydactyly) with cone-shaped epiphyses visible on X-ray. Facial features may include a round face, well-defined eyebrows, long eyelashes, a small nose with anteverted nostrils, a long philtrum, and thick lips. Joint limitations, particularly of the hands and wrists, are common and may worsen over time. Mild skin thickening on the hands and forearms, as well as hoarse voice, have also been reported. Internal organ involvement is generally mild compared to geleophysic dysplasia, though some patients may develop mild cardiac valve abnormalities or recurrent respiratory issues related to tracheal narrowing. There is currently no specific cure or targeted therapy for acromicric dysplasia. Management is supportive and multidisciplinary, focusing on orthopedic monitoring, management of joint stiffness through physical therapy, and surveillance for potential cardiac or respiratory complications. Growth hormone therapy has been attempted in some cases but generally shows limited efficacy. Carpal tunnel syndrome may develop and require surgical intervention. Regular follow-up with specialists in genetics, orthopedics, cardiology, and pulmonology is recommended to monitor for complications and optimize quality of life.
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Acromicric dysplasia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Acromicric dysplasia at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Acromicric dysplasia.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Acromicric dysplasia.
Community
No community posts yet. Be the first to share your experience with Acromicric dysplasia.
Start the conversation →Latest news about Acromicric dysplasia
No recent news articles for Acromicric dysplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Acromicric dysplasia
What is Acromicric dysplasia?
Acromicric dysplasia is a rare skeletal disorder characterized by severe short stature, short hands and feet, and mild facial dysmorphism. The condition is caused by mutations in the FBN1 gene (fibrillin-1), which plays a critical role in the formation of extracellular matrix microfibrils. Acromicric dysplasia belongs to a spectrum of acromelic dysplasias that also includes geleophysic dysplasia and Weill-Marchesani syndrome, all of which can result from specific mutations in FBN1 affecting the TGF-beta signaling pathway. Key clinical features include proportionate short stature that becomes
How is Acromicric dysplasia inherited?
Acromicric dysplasia follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Acromicric dysplasia typically begin?
Typical onset of Acromicric dysplasia is childhood. Age of onset can vary across affected individuals.